Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.

Igal RosensteinMarkus AxelssonLenka NovakovaKaj BlennowHenrik ZetterbergJan N Lycke

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)

cNFL is a robust and reliable biomarker of disease activity, treatment response, and prediction of disability and conversion from RRMS to SPMS. Our data suggest that cNFL should be included in the assessment of patients at MS-onset.

Keyphrases

disease activity
multiple sclerosis
systemic lupus erythematosus
rheumatoid arthritis
clinical practice
mass spectrometry
rheumatoid arthritis patients
ms ms
ankylosing spondylitis
cerebrospinal fluid
juvenile idiopathic arthritis
electronic health record
big data
deep learning